Efficacy of Rituximab Combined with CHOP for B Cell Non-Hodgkin's Lymphoma
10.3969/j.issn.1000-8179.2009.24.006
- VernacularTitle:利妥昔单抗联合CHOP综合治疗B细胞性非霍奇金淋巴瘤的临床研究
- Author:
Chunying XIE
;
Anwen LIU
;
Ling LI
;
Shunjin WANG
- Publication Type:Journal Article
- Keywords:
Non-Hodgkin lymphoma;
Rituximab;
CHOP regimen
- From:
Chinese Journal of Clinical Oncology
2009;36(24):1398-1400
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the therapeutic effects of Rituximab combined with CHOP on B cell non-Hodgkin's lymphoma. Methods: A prospective study with concurrent control group was carried out. A total of 60 cases of B cell non-Hodgkin's lympoma were divided into 2 groups. The 30 cases in the research group received Rituximab combined with CHOP regimen. The 30 cases in the control group were treated with CHOP regimen alone. CHOP regimen (Cyclophospham 600mg/m~2 IV, Vincristine 1.4mg/m~2 Ⅳ, and Adriamy-cin piarubicin 50mg/m~2 IV) was administered on the first day of chemotherapy course. Prednisone 100mg/m~2 was administered orally from the first day to the fifth day. The cycle was repeated every 21 days and the patients received at least 3-6 cycles of chemotherapy. The therapeutic effect was assessed. Results: The complete remission (CR) rate and total response rate were 66.7% (20/30) and 90.0% (27/30) in the research group and 39.97% (12/30) and 56.7% (17/30) in the control group. The therapeutic differences between the two groups showed a statistical significance (P＜0.05). Conclusion: Compared with CHOP regimen chemotherapy, Rituximab combined with CHOP regimen shows better therapeutic effect. The side effects in the research group are similar to those in the control group. Rituximab combined with CHOP regimen can be the first choice in the treatment for B cell non-Hodgkin's lymphoma.
